How healthcare LPs are thinking about the next fund cycle

The LP mood

LP appetite for healthcare venture is cautiously returning. The DPI-focused environment has favored funds with realized returns, not just paper markups.

Where allocations are moving

Toward specialist funds with clear category focus, and toward funds with genuinely differentiated deal access. Generalist late-stage funds are the primary casualty.

What this means for founders

The set of funds writing conviction seed and Series A checks in healthcare has become smaller and more specialized. Choose partners deliberately.

Long-horizon signals

LPs are increasingly asking about GP-led continuation vehicles for aging portfolios. Expect this to become normalized over the next two years.

Why patience became a selection criterion

LPs allocating to healthcare-focused funds are increasingly asking general partners how they plan to manage a longer path to liquidity, not just how they plan to source deals. This is a shift in emphasis rather than a new concern, but it now shows up explicitly in due diligence memos and reference calls in a way it did not several vintages ago.

Funds that can point to a credible secondary-sale playbook or a track record of structured partial exits are faring noticeably better in this environment than funds whose entire model depends on a traditional IPO or acquisition outcome arriving on schedule.

A composite allocator conversation

In a representative allocator conversation, the diligence team spent more time asking about a fund's follow-on reserve discipline than about its sourcing network, reflecting a broader realization that capital efficiency in the middle innings determines returns more than logo quality at entry. That is a meaningful change in what gets rewarded in a pitch to LPs.

General partners who adapted their reporting to emphasize reserve planning and portfolio triage found the conversations went faster and landed better.

The emerging bar for a first-time healthcare fund

First-time general partners raising healthcare-focused funds are facing a materially higher bar than generalist peers, because LPs burned by unrealistic exit timelines in prior vintages are now scrutinizing sector-specific assumptions more closely. A credible fund thesis has to explain not just where deals come from but how the fund plans to generate liquidity events on a realistic clinical and regulatory timeline, not a software-standard one.

This has pushed several emerging managers toward smaller first funds with narrower theses, on the logic that a demonstrable track record in one defensible niche is more fundable than a broad healthcare mandate with no proof points yet.

What this means for fund size and pacing

Larger allocators are increasingly comfortable committing to funds that plan slower deployment paces and larger reserve ratios, even if that means a longer gap between vintages. That patience is conditional, however, on general partners actually holding to the discipline rather than deploying at the old pace once capital is in hand, and LPs are building that expectation explicitly into side letters this cycle in a way they had not before.